A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With a Clinically Isolated Syndrome (CIS).

Trial Profile

A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With a Clinically Isolated Syndrome (CIS).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PreCISe
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 12 Jun 2012 Actual patient number changed from 482 to 481 according to ClinicalTrials.gov.
    • 12 Jun 2012 Actual end date changed from Oct 2010 to Jun 2010 as reported by ClinicalTrials.gov.
    • 16 Apr 2011 Five-year results presented at the 63rd Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top